Skip to main content
Premium Trial:

Request an Annual Quote

A 'Valuable Service' or an Exorbitant Mark-Up?


US Congressman Elijah Cummings, a Maryland Democrat and ranking member of the US House Oversight and Government Reform Committee, has launched an investigation into the pricing policies of companies that buy cancer drugs on a secondary market and then resell them to hospitals, reports Bloomberg's Drew Armstrong and Tom Randall. Cummings says the companies are adding a "steep mark-up" to the price of the drug, while the companies claim they provide a "valuable service" to hospitals, Armstrong and Randall write. According to a survey by the Premier Healthcare Alliance, the prices these companies sell the drugs for are, on average, seven times more expensive than typical prices. Cummings, who said the companies engage in "price gouging" in a statement emailed to Bloomberg, added that found one reseller who charged a hospital 80 times the typical price for the pediatric cancer drug cytarabine. He plans to investigate where the companies are getting their supplies, and how much their profits are, Armstrong and Randall say. The resellers say the mark-ups reflect their costs and the shortage of cancer drugs currently plaguing the US. Three of the five major resellers who received a letter from Cummings say they plan to cooperate, Bloomberg adds.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.